By targeting c‐Myc, novel therapeutic approaches may simultaneously inhibit tumour progression and reprogram the immune microenvironment, thereby enhancing ICI responsiveness and broadening clinical benefit in patients with TNBC. The gene discussed is MYC; the disease is neoplasm.